ASP-IHEALTH invests in the master fund กองทุนที่ลงทุนหลายกอง (JHHBIU2 LX, ARKG US). Actual total expense ratio (TER) 2.83% a year. Pays no dividends. Data as of 12 Nov 2026.
Asset Plus Innovative Healthcare Fund
Shows where this fund stands in its group. Not investment advice · Data as of 12 Nov 2026
ASP-IHEALTH is a fund of funds that puts 99.36% into units of other funds, spread across several funds
This fund's manager selects the funds and adjusts their weights. The funds it holds also charge their own fees
All funds, as disclosed in the AMC fact sheet · The stocks these funds hold are shown below · This fund's performance therefore depends on the funds it holds
Over the past year it was above its group median; over 5 years it returned −0.56% per year (Below the median)
| Return | SD | MDD | Return/SD | |
|---|---|---|---|---|
| YTD | +14.02% | −15.79% | ||
| 1D | −1.82% | −1.82% | ||
| 1W | +1.54% | −2.18% | ||
| 2W | −2.93% | −6.48% | ||
| 1M | +1.67% | −6.48% | ||
| 3M | −6.35% | −15.79% | ||
| 6M | +13.83% | −15.79% | ||
| 1Y | +18.91% | 24.71% | −15.79% | +0.77 |
| 3Y | +59.08%+16.74%/yr | 22.07% | −30.36% | +0.76 |
| 5Y | −2.77%−0.56%/yr | 23.49% | −44.60% | −0.02 |
| 7Y | +64.96%+7.41%/yr | 23.58% | −53.14% | +0.31 |
| MAX | +62.72%+6.59%/yr | 23.05% | −53.14% | +0.29 |
| Return | MDD | SD | Return/SD | |
|---|---|---|---|---|
| YTD | +14.02% | −15.79% | ||
| 1D | −1.82% | −1.82% | ||
| 1W | +1.54% | −2.18% |
Past performance is not a guarantee of future results
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Full year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.8 | −1.4 | −4.2 | +2.8 | +5.7 | +13.8 | −4.9 | +8.1 |
Largest drawdown in the selected period −53.14% Previous peak 9 Feb 2021 (NAV 19.7836) → Trough 16 Jun 2022 (NAV 9.2708) · Not back to the previous peak as of 12 Nov 2026
Currently −17.76% from the peak NAV of 19.7836 (9 Feb 2021)
Over 7 years, ASP-IHEALTH returned 0.31 per unit of SD, ranking 20 of 26 funds · The highest is FP HCARE-A (0.63)
กองทุนจะลงทุนในหรือมีไว้ซึ่งหน่วยลงทุนของกองทุนรวมตราสารทุนต่างประเทศ เช่น หน่วย CIS Its largest holdings are JHHBIU2 LX 73.25% · ARKG US 26.11% (fact sheet 30 Sep 2026)
Risk level 7 of 8 (High risk). Since 29 Mar 2019, its NAV has fallen as much as −53.14% from its peak.
Actual total expense ratio (TER) 2.83% a year, against a ceiling of 4.49%. Management fee 1.61%. Front-end fee 1.50%. Back-end fee 0.00%. (Fact sheet 31 Aug 2026)
No. Gains or losses accumulate in the NAV, and investors receive their return when they redeem units
Warning Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
Biotech company that develops drugs for RAS-driven cancers, such as pancreatic cancer
Biotech company that develops drugs for neurological conditions such as epilepsy and tremor
Develops drugs for genetic diseases, including Attruby for the heart disease ATTR-CM
European biotech that makes Vyvgart to treat autoimmune diseases such as myasthenia gravis
A US drug company making HIV treatment and prevention drugs, hepatitis drugs and cancer drugs
Based on each ETF's actual share of the fund's value · Weighted by each fund held × the stocks that fund holds, covering 100% of the money invested in other funds. Uses each fund's top 10, so figures are a minimum · JHHBIU2 LX as of 31 Aug 2026 · ARKG US as of 1 Oct 2026 · Illustrations are for explanation only, not individual stock recommendations
| 2W | −2.93% | −6.48% |
| 1M | +1.67% | −6.48% |
| 3M | −6.35% | −15.79% |
| 6M | +13.83% | −15.79% |
| 1Y | +18.91% | −15.79% | 24.71% | +0.77 |
| 3Y | +59.08%+16.74%/yr | −30.36% | 22.07% | +0.76 |
| 5Y | −2.77%−0.56%/yr | −44.60% | 23.49% | −0.02 |
| 7Y | +64.96%+7.41%/yr | −53.14% | 23.58% | +0.31 |
| MAX | +62.72%+6.59%/yr | −53.14% | 23.05% | +0.29 |
No. 1 is SCBGENOME(E) +55.13%
No. 1 is TBIOTECH +23.99% per year
No. 1 is TBIOTECH +8.06% per year
No. 1 is FP HCARE-A +9.94% per year
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 12 Nov 2026
| −3.0 |
| −1.3 |
| −1.7 |
| · |
| +14.0* |
| 2025 | +5.2 | −4.4 | −7.1 | −1.2 | −5.6 | +3.8 | +3.8 | +4.4 | +5.1 | +13.1 | +7.5 | −1.3 | +23.6 |
|---|
| 2024 | −2.4 | +5.8 | −1.8 | −8.5 | +2.3 | +2.4 | +4.7 | +1.5 | −1.9 | −0.8 | −1.8 | −9.1 | −10.3 |
|---|
| 2023 | +3.5 | −3.3 | +0.2 | +3.1 | +1.9 | +2.1 | +2.5 | −6.9 | −8.6 | −12.3 | +12.2 | +14.7 | +5.8 |
|---|
| 2022 | −17.9 | −0.7 | +0.2 | −13.5 | −5.8 | +1.9 | +8.9 | +1.3 | −2.6 | +6.5 | +3.3 | −0.7 | −20.3 |
|---|
| Average | −1.3 | −0.7 | −3.7 | +0.1 | −0.1 | +4.9 | +1.5 | +1.5 | −2.1 | +1.5 | +4.2 | +2.1 | +8.7 |
|---|
Minimum first purchase 1,000 THB, subsequent purchases 1,000 THB. Buy orders accepted until 15:30, sell orders until 15:30, and redemption proceeds are paid T+5
Almost fully hedged. As of 30 Sep 2026, 100.14% of the value of its foreign investments was hedged